Vision,
Reimagined.

Restoring sight for those with blinding diseases.

Powered by Optogenetics

We use the innovative technology of optogenetics to reprogram surviving neurons in the retina of the eye to sense light and send visual signals to the brain—restoring vision.

Leadership

Paul Bresge

Chief Executive Officer

Chris-Whitmore

Chris Whitmore, CPA

Chief Financial Officer

Peter Francis, MD, PhD

Chief Medical & Scientific Officer

Jenny Holt

Chief Development Officer

Our Pipeline

Bioengineered optogenetic medicines to preserve and restore vision for degenerative retinal diseases.

INDICATION
PROGRAM
DISCOVERY
IND-ENABLING
PHASE 1
PHASE 2/3
Retinitis Pigmentosa
RTX-015
Choroideremia
RTX-015
Stargardt’s Disease
RTX-021
Geographic Atrophy
RTX-021